RC
Remedium Capital Partners, LLC
Momentum followerQuality / disciplined sizingConcentrated strategy
Total reported value
$281.2M
Reporting period: 2026-03-31 · Number of holdings: 6
Remedium Capital Partners, LLC disclosed 6 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $281.2M and a quarterly turnover rate of 51.1%.
Personality snowflake
- Concentration
- 86.27
- Portfolio Stability
- 51.09
- Momentum/Contrarian
- 100
- Sector conviction
- 0
- Diversification
- 12
- Sizing Uniformity
- 94.06
Recent moves
Add DMRA
+1597.9% $50.2M
Trim APGE
0.0% $5.1M
Trim JBIO
0.0% -$2.2M
Trim SYRE
0.0% $25.7M
Trim ORKA
+0.9% $29.7M
Trim 38000Q201
0.0% $2.4M
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics INC | Stock-Other | 27.31% | -0.33% | +0.85% | |
| 2 | SYRE | Spyre Therapeutics INC | Stock-Other | 26.13% | -1.90% | — | |
| 3 | DMRA | Damora Therapeutics INC | Stock-Other | 18.84% | +17.21% | +1597.87% | |
| 4 | APGE | Apogee Therapeutics INC | Stock-Other | 17.47% | -8.41% | — | |
| 5 | JBIO | Jade Biosciences INC | Stock-Other | 7.88% | -6.42% | — | |
| 6 | ✓ | Crescent Biopharma INC. | Stock-Other | 2.36% | -0.16% | — |
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
Holding changes this quarter
Remedium Capital Partners, LLC's most significant position changes for 2026-03-31: Add: Damora Therapeutics INC (DMRA) — shares +1597.87%; Add: Oruka Therapeutics INC (ORKA) — shares +0.85%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DMRA | Damora Therapeutics INC | +17.2% | +1597.87% | Add |
| 2 | ✓ | Crescent Biopharma INC. | -0.2% | — | Unchanged |
| 3 | ORKA | Oruka Therapeutics INC | -0.3% | +0.85% | Add |
| 4 | SYRE | Spyre Therapeutics INC | -1.9% | — | Unchanged |
| 5 | JBIO | Jade Biosciences INC | -6.4% | — | Unchanged |
| 6 | APGE | Apogee Therapeutics INC | -8.4% | — | Unchanged |
FAQ
What is Remedium Capital Partners, LLC and what type of investor is it?
Remedium Capital Partners, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $281.2M, spread across 6 disclosed positions.
What are Remedium Capital Partners, LLC's largest equity positions?
Based on the latest 13F filing, Remedium Capital Partners, LLC's top holdings by market value are:
1. Oruka Therapeutics INC (ORKA) — $76.8M (27.3%)
2. Spyre Therapeutics INC (SYRE) — $73.5M (26.1%)
3. Damora Therapeutics INC (DMRA) — $53.0M (18.8%)
4. Apogee Therapeutics INC (APGE) — $49.1M (17.5%)
5. Jade Biosciences INC (JBIO) — $22.2M (7.9%)
What changes did Remedium Capital Partners, LLC make in its most recent portfolio filing?
In the latest quarter, Remedium Capital Partners, LLC was primarily adding exposure — initiating 0 new positions and adding to 2 existing holdings. The largest of these moves: Add: Damora Therapeutics INC (DMRA) — shares +1597.87%; Add: Oruka Therapeutics INC (ORKA) — shares +0.85%
What sectors does Remedium Capital Partners, LLC focus on?
Sector breakdown data is not yet available for Remedium Capital Partners, LLC. Check back after the next 13F processing cycle.